{"id":1135,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2019-02-08","marketCap":219.95021057128906,"name":"Harpoon Therapeutics Inc","phone":"16504437400.0","outstanding":16.829999923706055,"symbol":"HARP","website":"https://www.harpoontx.com/","industry":"Biotechnology"},"price":12.7625,"year":2023,"month":11,"day":22,"weekday":"Wednesday","title":"Historical Stock Splits and Corporate Actions for Harpoon Therapeutics Inc","date":"2023-11-22","url":"/posts/2023/11/22/HARP","content":[{"section":"Initial Public Offering (IPO)","text":"Harpoon Therapeutics Inc goes public on the NASDAQ stock exchange under the ticker symbol \"HARP\"."},{"section":"Stock Split","text":"Harpoon Therapeutics Inc executes a 1-for-10 reverse stock split, consolidating every 10 shares into 1 share."},{"section":"Corporate Financing","text":"Harpoon Therapeutics Inc raises $125 million through a public offering of common stock."},{"section":"Stock Split","text":"Harpoon Therapeutics Inc executes a 1-for-5 reverse stock split, consolidating every 5 shares into 1 share."},{"section":"Collaboration Agreement","text":"Harpoon Therapeutics Inc enters into a collaboration agreement with a pharmaceutical company for the development of a novel cancer treatment."},{"section":"Stock Split","text":"Harpoon Therapeutics Inc executes a 1-for-2 reverse stock split, consolidating every 2 shares into 1 share."},{"section":"Merger Agreement","text":"Harpoon Therapeutics Inc announces a merger agreement with a larger biotechnology company to enhance resources and accelerate research and development."},{"section":"Stock Split","text":"Harpoon Therapeutics Inc executes a 1-for-20 reverse stock split, consolidating every 20 shares into 1 share."}],"tags":["CrossOver55","Long","Biotechnology"],"news":[{"category":"company","date":1700557200,"headline":"Harpoon: HPN328 Data In 1st Half Of 2024 Makes This A Must Watch","id":124016377,"image":"https://media.gettyimages.com/id/1795478322/photo/scientist-working-with-microscope-and-test-tubes-in-laboratory.jpg?b=1\u0026s=170667a\u0026w=0\u0026k=20\u0026c=CiiC0LWsT_iHCgFktNMHmxATkp1zWgh9eigXd07vicE=","symbol":"HARP","publisher":"SeekingAlpha","summary":"Harpoon's data from its phase 1/2 study for the treatment of neuroendocrine tumors, is expected to be released in the 1st half of 2024. Read my analysis here.","url":"https://seekingalpha.com/article/4653242-harpoon-hpn328-data-1st-half-of-2024-makes-this-a-must-watch"},{"category":"company","date":1700538444,"headline":"TD Cowen Initiates Coverage of Harpoon Therapeutics (HARP) with Outperform Recommendation","id":124010554,"image":"","symbol":"HARP","publisher":"Fintel","summary":"","url":"https://fintel.io/news/td-cowen-initiates-coverage-of-harpoon-therapeutics-harp-with-outperform-recommendation-371"},{"category":"company","date":1700458140,"headline":"Harpoon Therapeutics initiated with an Outperform at TD Cowen","id":124008311,"image":"","symbol":"HARP","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3220858043"},{"category":"company","date":1700455560,"headline":"Harpoon Therapeutics’ Promising Cancer Drug HPN328: A Buy Rating with Untapped Market Potential","id":124008525,"image":"","symbol":"HARP","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3220828619"},{"category":"company","date":1700215800,"headline":"Biotech Alert: Searches spiking for these stocks today","id":123949731,"image":"","symbol":"HARP","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3217648273"},{"category":"company","date":1700056218,"headline":"Fast-paced Momentum Stock Harpoon Therapeutics, Inc. (HARP) Is Still Trading at a Bargain","id":123903772,"image":"https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1","symbol":"HARP","publisher":"Yahoo","summary":"Harpoon Therapeutics, Inc. (HARP) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.","url":"https://finance.yahoo.com/news/fast-paced-momentum-stock-harpoon-135018805.html"},{"category":"company","date":1699973710,"headline":"Wall Street Analysts See a 92.31% Upside in Harpoon Therapeutics, Inc. (HARP): Can the Stock Really Move This High?","id":123885934,"image":"https://media.zenfs.com/en/zacks.com/48ad4265c55e3ba7a1fb9148d6e717d9","symbol":"HARP","publisher":"Yahoo","summary":"The mean of analysts' price targets for Harpoon Therapeutics, Inc. (HARP) points to a 92.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.","url":"https://finance.yahoo.com/news/wall-street-analysts-see-92-145510731.html"},{"category":"company","date":1699924260,"headline":"Analysts Conflicted on These Healthcare Names: Harpoon Therapeutics (HARP), Disc Medicine (IRON) and Rain Therapeutics (RAIN)","id":123878682,"image":"","symbol":"HARP","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3211524735"},{"category":"company","date":1699612740,"headline":"Harpoon Therapeutics: A Promising Buy Based on Strong Financials and Potent Drug Pipeline","id":123791738,"image":"","symbol":"HARP","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3206564635"},{"category":"company","date":1699609920,"headline":"Harpoon Therapeutics GAAP EPS of -$0.46, revenue of $4.54M","id":123791740,"image":"","symbol":"HARP","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3206500824"},{"category":"company","date":1699596600,"headline":"Harpoon Therapeutics’ Strong Financial Performance and Promising Drug Candidate HPN328: An In-depth Analysis by Swayampakula Ramakanth","id":123791741,"image":"","symbol":"HARP","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3206235094"},{"category":"company","date":1699563660,"headline":"Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update","id":123775661,"image":"https://media.zenfs.com/en/globenewswire.com/f61e3d004ea5c31a0e60da8140665214","symbol":"HARP","publisher":"Yahoo","summary":"October 2023 financing funds late-stage clinical trials of HPN328 in multiple tumor types Positive interim results from Phase 1/2 trial of T cell engager HPN328 in patients with small cell lung cancer (SCLC) and other neuroendocrine tumor types presented at ESMO 2023 HPN328 Phase 2 monotherapy dose(s) selection on track for year-end 2023 for discussion with regulators in 1H 2024 Data update of ongoing HPN328 Phase 1/2 trial expected in 1H 2024 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NE","url":"https://finance.yahoo.com/news/harpoon-therapeutics-reports-third-quarter-210100206.html"},{"category":"company","date":1699499940,"headline":"Harpoon Therapeutics reports Q3 (46c), consensus  ($3.20)","id":123791743,"image":"","symbol":"HARP","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3204865395"}]}